[go: up one dir, main page]

MA40363A - Agents de liaison de rspo1 et leurs utilisations - Google Patents

Agents de liaison de rspo1 et leurs utilisations

Info

Publication number
MA40363A
MA40363A MA040363A MA40363A MA40363A MA 40363 A MA40363 A MA 40363A MA 040363 A MA040363 A MA 040363A MA 40363 A MA40363 A MA 40363A MA 40363 A MA40363 A MA 40363A
Authority
MA
Morocco
Prior art keywords
binding agents
rspo1 binding
rspo1
rspo
administering
Prior art date
Application number
MA040363A
Other languages
English (en)
Inventor
Austin Gurney
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MA40363A publication Critical patent/MA40363A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des agents de liaison de rspo, en particulier des anticorps qui se lient spécifiquement au rspol humain. L'invention concerne également des procédés de traitement de cancer et d'autres maladies, consistant à administrer une quantité thérapeutiquement efficace d'un agent ou d'un anticorps de la présente invention à un patient en ayant besoin.
MA040363A 2014-08-15 2015-08-14 Agents de liaison de rspo1 et leurs utilisations MA40363A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462037880P 2014-08-15 2014-08-15

Publications (1)

Publication Number Publication Date
MA40363A true MA40363A (fr) 2017-06-21

Family

ID=55304654

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040363A MA40363A (fr) 2014-08-15 2015-08-14 Agents de liaison de rspo1 et leurs utilisations

Country Status (9)

Country Link
US (1) US20170247437A1 (fr)
EP (1) EP3180027A4 (fr)
JP (1) JP2017526356A (fr)
CN (1) CN106714833A (fr)
AU (1) AU2015301538A1 (fr)
CA (1) CA2958144A1 (fr)
MA (1) MA40363A (fr)
MX (1) MX2017001983A (fr)
WO (1) WO2016025797A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109529040B (zh) * 2017-09-21 2020-11-13 华东师范大学 LGR4和R-spondin结合抑制剂及其在肿瘤治疗中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2579142A1 (fr) * 2004-09-13 2006-03-23 Macrogenics, Inc. Anticorps humanises contre le virus du nil occidental ainsi qu'utilisations therapeutiques et prophylactiques associees
CA2591665C (fr) * 2004-12-20 2015-05-05 Crucell Holland B.V. Molecules de liaison capables de neutraliser le virus du nil occidental et utilisations correspondantes
BRPI0712222B1 (pt) * 2006-06-02 2021-10-13 Aveo Pharmaceuticals, Inc. Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina
NZ573819A (en) * 2006-06-02 2011-09-30 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
KR20100044160A (ko) * 2007-06-12 2010-04-29 와이어쓰 엘엘씨 항-ｃｄ20 치료 조성물 및 방법
EP2313435A4 (fr) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3)
TWI506037B (zh) * 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
US20120141497A1 (en) * 2009-03-11 2012-06-07 Wyeth Llc Methods of purifying small modular immunopharmaceutical proteins
KR20120027031A (ko) * 2009-06-18 2012-03-20 와이어쓰 엘엘씨 소형 모듈 면역제약용 동결건조 제제
RU2646139C1 (ru) * 2009-09-03 2018-03-01 Мерк Шарп И Доум Корп. Анти-gitr-антитела
US8663950B2 (en) * 2010-01-11 2014-03-04 Arizona Board Of Regents Production of a monoclonal antibody therapeutic against west nile virus in plants
CN104023746B (zh) * 2011-07-15 2016-08-17 昂考梅德药品有限公司 Rspo结合剂和其应用

Also Published As

Publication number Publication date
JP2017526356A (ja) 2017-09-14
CN106714833A (zh) 2017-05-24
US20170247437A1 (en) 2017-08-31
CA2958144A1 (fr) 2016-02-18
WO2016025797A4 (fr) 2016-03-31
WO2016025797A1 (fr) 2016-02-18
EP3180027A4 (fr) 2018-01-10
AU2015301538A1 (en) 2017-03-02
EP3180027A1 (fr) 2017-06-21
MX2017001983A (es) 2017-05-23

Similar Documents

Publication Publication Date Title
EP4276114A3 (fr) Anticorps à domaine unique ciblant cd20
MX2020001513A (es) Agentes de union a clec9a y su uso.
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
MX2022001105A (es) Anticuerpos anti tigit.
NZ738008A (en) Tigit-binding agents and uses thereof
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
PH12016501644A1 (en) Binding proteins and methods of use thereof
MX2017016253A (es) Anticuerpos para cd40.
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
NZ707086A (en) Anti-cd40 antibodies and methods of use
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
MX2022000317A (es) Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5.
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.